-
Something wrong with this record ?
DNA repair capacity and response to treatment of colon cancer
P. Vodicka, S. Vodenkova, T. Buchler, L. Vodickova,
Language English Country Great Britain
Document type Journal Article, Research Support, Non-U.S. Gov't, Review
Grant support
NV15-27580A
MZ0
CEP Register
Digital library NLK
Full text - Article
NLK
PubMed Central
from 2015 to 1 year ago
ProQuest Central
from 2000-02-01 to 2020-12-31
Health & Medicine (ProQuest)
from 2000-02-01 to 2020-12-31
PubMed
31691643
DOI
10.2217/pgs-2019-0070
Knihovny.cz E-resources
- MeSH
- Cell Death drug effects MeSH
- Epigenesis, Genetic genetics MeSH
- Humans MeSH
- Mutation MeSH
- Colonic Neoplasms drug therapy genetics pathology MeSH
- Genomic Instability drug effects genetics MeSH
- DNA Repair drug effects MeSH
- DNA Damage drug effects MeSH
- Prognosis MeSH
- Gene Expression Regulation, Neoplastic drug effects MeSH
- Check Tag
- Humans MeSH
- Publication type
- Journal Article MeSH
- Research Support, Non-U.S. Gov't MeSH
- Review MeSH
DNA repair, a complex biological process, ensures genomic integrity. Alterations in DNA repair, occurring in many cancers, contribute to the accumulation of mutations in the genome, resulting in genomic instability and cancer progression. DNA repair also plays a substantial role in response to chemotherapeutics: rapidly dividing colon cancer cells, vulnerable to DNA-damaging agents and overcoming DNA repair, undergo cell death. DNA repair capacity represents a complex biomarker, integrating gene variants, gene expressions, the stability of gene products, the effect of inhibitors/stimulators, lifestyle and environmental factors. Here, we discuss DNA repair capacity in sporadic colon cancer, a frequent malignancy worldwide, in relation to tumor heterogeneity, prognosis and prediction, measurements in surrogate and target tissues and suggest important tasks to be addressed.
References provided by Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc20025555
- 003
- CZ-PrNML
- 005
- 20201222153948.0
- 007
- ta
- 008
- 201125s2019 xxk f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.2217/pgs-2019-0070 $2 doi
- 035 __
- $a (PubMed)31691643
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xxk
- 100 1_
- $a Vodicka, Pavel $u Department of Molecular Biology of Cancer, Institute of Experimental Medicine, The Czech Academy of Sciences, Prague, Czech Republic. Institute of Biology & Medical Genetics, First Faculty of Medicine, Charles University, Prague, Czech Republic. Laboratory of Cancer Treatment and Tissue Regeneration, Faculty of Medicine & Biomedical Center in Pilsen, Charles University, Pilsen, Czech Republic.
- 245 10
- $a DNA repair capacity and response to treatment of colon cancer / $c P. Vodicka, S. Vodenkova, T. Buchler, L. Vodickova,
- 520 9_
- $a DNA repair, a complex biological process, ensures genomic integrity. Alterations in DNA repair, occurring in many cancers, contribute to the accumulation of mutations in the genome, resulting in genomic instability and cancer progression. DNA repair also plays a substantial role in response to chemotherapeutics: rapidly dividing colon cancer cells, vulnerable to DNA-damaging agents and overcoming DNA repair, undergo cell death. DNA repair capacity represents a complex biomarker, integrating gene variants, gene expressions, the stability of gene products, the effect of inhibitors/stimulators, lifestyle and environmental factors. Here, we discuss DNA repair capacity in sporadic colon cancer, a frequent malignancy worldwide, in relation to tumor heterogeneity, prognosis and prediction, measurements in surrogate and target tissues and suggest important tasks to be addressed.
- 650 _2
- $a buněčná smrt $x účinky léků $7 D016923
- 650 _2
- $a nádory tračníku $x farmakoterapie $x genetika $x patologie $7 D003110
- 650 _2
- $a poškození DNA $x účinky léků $7 D004249
- 650 _2
- $a oprava DNA $x účinky léků $7 D004260
- 650 _2
- $a epigeneze genetická $x genetika $7 D044127
- 650 _2
- $a regulace genové exprese u nádorů $x účinky léků $7 D015972
- 650 _2
- $a nestabilita genomu $x účinky léků $x genetika $7 D042822
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a mutace $7 D009154
- 650 _2
- $a prognóza $7 D011379
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a práce podpořená grantem $7 D013485
- 655 _2
- $a přehledy $7 D016454
- 700 1_
- $a Vodenkova, Sona $u Department of Molecular Biology of Cancer, Institute of Experimental Medicine, The Czech Academy of Sciences, Prague, Czech Republic. Institute of Biology & Medical Genetics, First Faculty of Medicine, Charles University, Prague, Czech Republic. Department of Medical Genetics, Third Faculty of Medicine, Charles University, Ruska 2411/87, 100 00 Prague, Czech Republic.
- 700 1_
- $a Buchler, Tomas $u Department of Oncology, First Faculty of Medicine, Charles University & Thomayer Hospital, Prague, Czech Republic.
- 700 1_
- $a Vodickova, Ludmila $u Department of Molecular Biology of Cancer, Institute of Experimental Medicine, The Czech Academy of Sciences, Prague, Czech Republic. Institute of Biology & Medical Genetics, First Faculty of Medicine, Charles University, Prague, Czech Republic. Laboratory of Cancer Treatment and Tissue Regeneration, Faculty of Medicine & Biomedical Center in Pilsen, Charles University, Pilsen, Czech Republic.
- 773 0_
- $w MED00008477 $t Pharmacogenomics $x 1744-8042 $g Roč. 20, č. 17 (2019), s. 1225-1233
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/31691643 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y a $z 0
- 990 __
- $a 20201125 $b ABA008
- 991 __
- $a 20201222153944 $b ABA008
- 999 __
- $a ok $b bmc $g 1599700 $s 1116241
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2019 $b 20 $c 17 $d 1225-1233 $e 20191106 $i 1744-8042 $m Pharmacogenomics $n Pharmacogenomics $x MED00008477
- GRA __
- $a NV15-27580A $p MZ0
- LZP __
- $a Pubmed-20201125
